“Lung cancer and liver cancer are in the top three deadliest cancers in the world, simply because we catch it way too late,” said Ilay Marom, the co-founder and Chief Operating Officer at NaNose Medical.
Founded around five and a half years ago, NaNose Medical is working to change that reality. Launched “with the purpose of revolutionizing screening tests and early diagnosis,” Marom explained in conversation with CTech, the Israeli startup is pioneering non-invasive diagnostics based on breath biomarkers. It’s technology that holds particular significance for the early detection and future treatment of liver disease and lung cancer.
“Everybody knows early detection saves lives,” he continued. “Everybody knows about mammograms for breast cancer or colonoscopy for gastric cancer, but for several conditions like lung cancer and liver cancer, there’s no equivalent test.”
The technology behind NaNose Medical comes from over a decade of research at Israel’s Technion Institute. “The inventor, Professor Hossam Haick, who is a partner in our company, approached the co-founders, and then we started this company.”
Marom says his personal involvement stems from a desire “to be involved with an impactful company that uses deep tech in order to help the world.”
Today, the startup employs 14 people, led by CEO Orit Marom-Albeck, and is focused on commercializing its breath-based diagnostic system, which bypasses traditional diagnostic tools that Marom describes as outdated.
“The way to screen patients today uses very old and non-advanced systems like blood pressure and ECG. These kinds of machines have been around for 30, 40, 50 years,” he said.
Keep reading at calcalistech.com.
NaNose Medical inventor and Co-founder is Technion Professor Hossam Haick.
